You are using an older browser version. Please use a supported version for the best MSN experience.

BMO's Evan Seigerman breaks down the Zantac trial

Evan Siegerman, BMO Capital Markets, joins 'Closing Bell' to discuss the trial over Zantac and the potential impact on drugmakers.

UP NEXT

UP NEXT

image beaconimage beaconimage beacon